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Tumor necrosis factor (TNF)-alpha inhibitors play an important role in the treatment of immun-mediated
diseases such as Crohn's disease. But they also have been related to increased risk for disseminated
Mycobacterium tuberculosis infections and paradoxical response to antimycobacterial treatment. Here we
report a disseminated tuberculosis case and a paradoxical response to treatment after receiving TNF-
inhibitor agent Inﬂiximab for Crohn's disease. The patient had a severe clinical condition before the
antimycobacterial treatment and although proper treatment was initiated his radiological ﬁndings were
worsened one month after initiation of the treatment. All control microbologic tests for secondary in-
fections were negative and this situation was accepted as a paradoxical response to antimycobacterial
treatment and treatment was continued with the same regimen. At the end of the second month of the
treatment, most of the symptoms disappeared and chest radiograph ﬁndings were better than the
previous one. In conclusion, TNF-alpha inhibitor therapy increases risk of mycobacterial infections and
patients should be examined carefully about tuberculosis before starting this therapy. Also, it is
important for physicians to recognize and know how to manage paradoxical response related to TNF-
alpha inhibitors during anti-tuberculosis treatment.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Crohn's disease is an idiopathic inﬂammatory bowel disease,
treatment of which consists of administration of high dose mesa-
lazine in mild cases, corticosteroids in moderate to severe cases and
immunosuppressives [Tumor necrosis factor (TNF)-alpha blockers,
azathioprine, methotrexate] for corticosteroid dependent patients
or corticosteroid refractory disease [1,2]. One of the most important
side effects of TNF-alpha blockers is an increased risk for reac-
tivation of latent tuberculosis and an increased risk for dissemi-
nated tuberculosis infection [3,4]. Besides, there is a phenomenon
called as ‘’paradoxical reaction’’ during the treatment of tubercu-
losis in which pre-existing lesions worsen or new lesions appear
despite of improving symptoms of the patient [5,6]. There are somegüs Hastalıkları ve Cerrahisi
ervisi, Gaziler Caddesi, 35210
, þ90 507 6507616 (mobile);
).
Ltd. This is an open access article upublished reports in which paradoxical reaction to anti-
mycobacterial treatment was related to discontinuation of TNF-
alpha blockers after the diagnosis of an active tuberculosis infec-
tion [7].
We report a case of a Crohn's disease patient with disseminated
tuberculosis caused by administration of TNF-alpha inhibitor agent
Inﬂiximab and paradoxical response to antimycobacterial treat-
ment after this agent was stopped.Case presentation
A 45-year-old man was referred to our clinic from gastroen-
terology department of another hospital. He was diagnosed as
Crohn's disease in 2007 and treated with mesalazine for 2 years. In
2009, this treatment regime was stopped because of refractory
symptoms and azathioprine was administered in combination
with oral glucocorticoids. Again because of inadequate control,
therapy with Inﬂiximab was initiated in January 2013. After 3
doses of Inﬂiximab therapy, the patient exhibited dyspnea, night
sweating and intermittent high fever. Examination of bloodnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Chest radiographs of the patient from left to right; on admission, one month after initiation of the treatment, two months after initiation of the treatment.
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mm3), lymphopenia (460/mm3) and anemia (haemoglobin:10.6 g/
dl). Number of thrombocytes and results of blood chemistry were
within normal limits. Erythrocyte sedimentation rate was 114 mm/
h and serum level of C-reactive protein was 12.5 mg/dl. Tuberculin
skin test (TST) was measured as 13 mm at the end of 72 h and
anti-HIV antibody tests were negative. Chest radiograph ﬁndings
were including small nodules throughout both lungs which were
compatible with miliary tuberculosis (Fig. 1). Computerized To-
mography (CT) report was deﬁning granular shadows and multiple
nodules with different sizes especially located in the upper and
middle zones of the both lungs (Fig. 2). Also there were para-
tracheal, precarinal, bilateral hilar, aorticopulmonary and sub-
carinal enlarged lymph nodes whose greatest diameter was
measured as 15 mm. According to these images, possible di-
agnoses were listed as atypical infectious disease, sarcoidosis,
miliary tuberculosis, pneumoconiosis and metastatic nodules. Af-
ter the Haematology consultation, hemogram results of the pa-
tient were related to Azathioprine and this drug was discontinued.
Also Inﬂiximab was stopped because of high possibility of active
tuberculosis infection, with the consultation of gastroenterology.
Positron Emission Tomography-Computerized Tomography (PET-
CT) was performed and different focuses showed pathological 18-
Fluorodeoxyglucose (18-FDG) uptake (several mediastinal lymph
nodes SUVmax ¼ 7.4, nodules of the lung parenchymeFig. 2. Thorax-CT images of tSUVmax ¼ 6.1, lymph nodes of the abdomen SUVmax ¼ 5.8, spleen
SUVmax ¼ 8.9, supradiaphragmatic lymph nodes and liver
SUVmax ¼ 5.4) (Fig. 3). Involvement of the spleen and lymph nodes
were also suggesting lymphoma. Endobronchial Ultrasound
Bronchoscopy (EBUS) was performed for both isolation of infec-
tious agent and examination of enlarged mediastinal lymph nodes.
Subcarinal and lower paratracheal lymph nodes were sampled by
EBUS-guided ﬁne needle aspiration biopsy. Pathologic view of the
subcarinal lymph node biopsy was consistent with caseating
granuloma and M. tuberculosis was isolated from both bronchial
aspiration ﬂuid and lymph node biopsy sample. So patient was
diagnosed as disseminated tuberculosis disease and anti-
mycobacterial treatment was initiated (Isoniazid 300 mg/day,
Rifampicin 600 mg/day, Pyrazinamide 1500 mg/day, Ethambutol
1200 mg/day). One month after the initiation of antimycobacterial
therapy, symptoms of the patient were decreased but chest
radiograph (Fig. 1) and CT scan ﬁndings were worsened (Fig. 4).
Fiberoptic Bronchoscopy (FOB) was done and bronchoscopic
aspiration and bronchoalveolar lavage (BAL) ﬂuids were taken for
microbiological tests. All tests were negative for fungal agents,
Pneumocystis jiroveci, viruses, bacteria and no asido-resistant ba-
cillus was isolated. This situation was accepted as a paradoxical
response to antimycobacterial treatment and treatment regimen
was not changed. At the end of the second month of the treat-
ment, most of the symptoms disappeared and chest radiographhe patient on admission.
Fig. 3. PET-CT images of the patient.
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under treatment and has a better health condition.
Discussion
We described a disseminated tuberculosis case with paradoxical
response to antimycobacterial treatment associated with TNF-
alpha neutralizing agent Inﬂiximab.
Despite effectiveness of TNF-alpha inhibitors in treatment of
immun-mediated diseases such as Crohn's disease, they also have
been related to disseminated tuberculosis infection as a side effect
[8]. Because TNF-alpha has a crucial role in protective immunity
againstM. tuberculosis infection and its blockage results with severe
mycobacterium infections [9]. That's why, appropriate screening of
patients is needed by using TST, a careful medical history of risk
factors for tuberculosis and chest radiographs before starting the
therapy [10]. Although diameter of 10 mm is accepted for the
positiveness of TST in immunocompetent patients, diameter equal
to 5 mm or greater should be accepted as a positive result in
immunosuppressed patients, as in this case [11]. Immunosup-
pressed patients should receive chemoprohylaxis with Isoniazid
(300 mg/day) for 9 months. An alternative for Isoniazid isRifampicin (600 mg/day) for 4 months [12]. Unfortunately, this
patient had no chest radiograph and TST before receiving Inﬂix-
imab therapy.
Keane et al. reported 70 patients who had tuberculosis during
and after Inﬂiximab therapy. Seventeen of them had disseminated
tuberculosis, median interval from the beginning of the Inﬂiximab
therapy until the development of tuberculosis was 12 weeks (range
1e52 weeks) and in 48 patients tuberculosis developed after 3 or
fewer infusions [13]. Consistent with their data, patient in this case
had received this drug for 3 times in 3 months.
Mechanism of paradoxical response to antimycobacterial
treatment is still uncertain. Immunorestitution phenomenon was
suggested to explain this response. According this phenomenon,
changes in cellular and cytokine patterns after the initiation of
antimycobacterial treatment and prompt recovery of the immune
system are the reasons of paradoxical reaction. As a result, an
overwhelming immunorestitution may produce immunopatho-
logical damage at the tissue level [14].
Although discontinuation of TNF-alpha blockers is suggested
after the diagnosis of active tuberculosis infection, there are some
evidences that this also causes paradoxical response and
resumption of TNF-alpha blockers with antimycobacterial
Fig. 4. Thorax-CT images of the patient one month after initiation of the treatment.
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with paradoxical response [7,15]. Inﬂiximab therapy was stopped
in this case.
Paradoxical response occurs in 10e15% of active tuberculosis
patients and the median time to the development of paradoxical
response is 2 months in HIV-negative patients (from 14 days to 270
days) [16]. In both HIV-negative and positive patients it occurs
more frequently with extrapulmonary tuberculosis and associated
with lymphopenia at the baseline [17,18]. Age, sex and co-
morbidities have no relation with this response. Patient in this
case had disseminated tuberculosis, low number of lymphocytes on
admission and paradoxical response occurred one month after
initiation of the treatment.
There are no international guidelines for the treatment of par-
adoxical response. However, continuation of the same anti-
mycobacterial drugs and administration of corticosteroids are
recommended [19]. Besides, secondary infections, inadequate anti-
tuberculosis treatment and adverse reactions due to anti-
mycobacterial therapy should be excluded. Generally this response
is transient and most of the patients recover with conservative or
medical treatment. Corticosteroids were not administered in this
case and treatment regimen of the patient was not changed. This
patient is still under treatment without a sign of relapse.
In conclusion, TNF-alpha inhibitor therapy increases risk of
mycobacterial infections and patients should be examined carefully
about tuberculosis before starting this therapy. Also it is important
for physicians to recognize and know how to manage paradoxical
response related to TNF-alpha inhibitors, during anti-tuberculosis
treatment.Written consent
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